These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15198787)

  • 1. The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis.
    Wyatt KM; Dimmock PW; Ismail KM; Jones PW; O'Brien PM
    BJOG; 2004 Jun; 111(6):585-93. PubMed ID: 15198787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
    Lethaby AE; Vollenhoven BJ
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.
    Segebladh B; Borgström A; Nyberg S; Bixo M; Sundström-Poromaa I
    Am J Obstet Gynecol; 2009 Aug; 201(2):139.e1-8. PubMed ID: 19398092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update.
    McLaren JS; Morris E; Rymer J
    Menopause Int; 2012 Jun; 18(2):68-72. PubMed ID: 22611225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptoms of premenstrual syndrome and their association with migraine headache.
    Martin VT; Wernke S; Mandell K; Ramadan N; Kao L; Bean J; Liu J; Zoma W; Rebar R
    Headache; 2006 Jan; 46(1):125-37. PubMed ID: 16412160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis.
    Wu D; Hu M; Hong L; Hong S; Ding W; Min J; Fang G; Guo W
    Arch Gynecol Obstet; 2014 Sep; 290(3):513-23. PubMed ID: 24728145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms.
    Adashi EY
    Hum Reprod; 1994 Jul; 9(7):1380-97. PubMed ID: 7962453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
    Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
    Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The need for add-back with gonadotrophin-releasing hormone agonist therapy.
    Studd J; Leather AT
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():1-4. PubMed ID: 8916978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
    Surrey ES
    Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discussion: 'Add-back regimens in patients using a GnRH agonist for premenstrual dysphoric disorder' by Segebladh et al.
    Jungheim ES; Kenerson JJ; Foyouzi-Yousefi N; Allsworth JE; Marquard KL
    Am J Obstet Gynecol; 2009 Aug; 201(2):e1-5. PubMed ID: 19646561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What's Stopping Us? Using GnRH Analogs With Stable Hormone Addback in Treatment-Resistant Premenstrual Dysphoric Disorder: Practical Guidelines and Risk-Benefit Analysis for Long-term Therapy.
    Wagner-Schuman M; Kania A; Barone JC; Ross JM; Mulvihill A; Eisenlohr-Moul TA
    J Clin Psychiatry; 2023 Jun; 84(4):. PubMed ID: 37341478
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review.
    Wyatt K; Dimmock P; Jones P; Obhrai M; O'Brien S
    BMJ; 2001 Oct; 323(7316):776-80. PubMed ID: 11588078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis.
    Akira S; Mine K; Kuwabara Y; Takeshita T
    Med Sci Monit; 2009 Jan; 15(1):CR1-4. PubMed ID: 19114964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal management of premenstrual syndrome.
    Usman SB; Indusekhar R; O'Brien S
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):251-60. PubMed ID: 17761457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose effects of progesterone in add-back therapy during GnRHa treatment.
    Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
    J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The premenstrual syndrome. Effects of "medical ovariectomy".
    Muse KN; Cetel NS; Futterman LA; Yen SC
    N Engl J Med; 1984 Nov; 311(21):1345-9. PubMed ID: 6387488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial.
    Agha-Hosseini M; Kashani L; Aleyaseen A; Ghoreishi A; Rahmanpour H; Zarrinara AR; Akhondzadeh S
    BJOG; 2008 Mar; 115(4):515-9. PubMed ID: 18271889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bone loss induced by GnRHa treatment in women].
    Matsuo H
    Nihon Rinsho; 2003 Feb; 61(2):314-8. PubMed ID: 12638227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.